GDTC vs GLSI

CytoMed Therapeutics Limited vs Greenwich LifeSciences, Inc. — Valuation Comparison 2026

GDTC

Biotechnology
CytoMed Therapeutics Limited
Quality
5.1
out of 10
Value Trap
12
SAFE
Price
$1.14
Last close
Models
9/13
Active
VS

GLSI

Biotechnology
Greenwich LifeSciences, Inc.
Quality
4.0
out of 10
Value Trap
Price
$28.99
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType GDTC Fair ValueGDTC Upside GLSI Fair ValueGLSI Upside
Bayesian DCF Intrinsic $0.32 -72.2% $7.90 -72.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $0.37 -67.1% $0.58 -98.0%
PWERM Option-Based $1.14 -0.4% $27.15 -6.3%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for GDTC vs GLSI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GDTC vs GLSI — Which Stock Is More Undervalued?

GDTC scores higher with a 5.1/10 quality rating vs GLSI's 4.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing CytoMed Therapeutics Limited (GDTC) and Greenwich LifeSciences, Inc. (GLSI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GDTC currently trades at $1.14 with a QOC of 5.1/10, while GLSI trades at $28.99 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).